AJP - Heart Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 297: H1930-H1939, 2009. First published September 18, 2009; doi:10.1152/ajpheart.00129.2009
0363-6135/09 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
297/5/H1930    most recent
00129.2009v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Smolock, E. M.
Right arrow Articles by Moreland, R. S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smolock, E. M.
Right arrow Articles by Moreland, R. S.

siRNA-mediated knockdown of h-caldesmon in vascular smooth muscle

Elaine M. Smolock,1,* Danielle M. Trappanese,1,* Shaohua Chang,3 Tanchun Wang,1 Paul Titchenell,1 and Robert S. Moreland1,2,3

Departments of 1Pharmacology and Physiology and 2Pathology and Laboratory Medicine, Drexel University College of Medicine, and 3Division of Urology, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Submitted February 6, 2009 ; accepted in final form September 15, 2009

Smooth muscle contraction involves phosphorylation of the regulatory myosin light chain. However, this thick-filament system of regulation cannot account for all aspects of a smooth muscle contraction. An alternate site of contractile regulation may be in the thin-filament-associated proteins, in particular caldesmon. Caldesmon has been proposed to be an inhibitory protein that acts either as a brake to stop any increase in resting or basal tone, or as a modulatory protein during contraction. The goal of this study was to use short interfering RNA technology to decrease the levels of the smooth muscle-specific isoform of caldesmon in intact vascular smooth muscle tissue to determine more carefully what role(s) caldesmon has in smooth muscle regulation. Intact strips of vascular tissue depleted of caldesmon produced significant levels of shortening velocity, indicative of cross-bridge cycling, in the unstimulated tissue and exhibited lower levels of contractile force to histamine. Our results also suggest that caldesmon does not play a role in the cooperative activation of unphosphorylated cross bridges by phosphorylated cross bridges. The velocity of shortening of the constitutively active tissue and the high basal values of myosin light chain phosphorylation suggest that h-caldesmon in vivo acts as a brake against contractions due to basally phosphorylated myosin. It is also possible that phosphorylation of h-caldesmon alone in the resting state may be a mechanism to produce increases in force without stimulation and increases in calcium. Disinhibition of h-caldesmon by phosphorylation would then allow force to be developed by activated myosin in the resting state.

myosin light chain; shortening velocity; cooperativity; carotid artery; cross-bridge cycling



Address for reprint requests and other correspondence: R. S. Moreland, Dept. of Pharmacology and Physiology, Drexel Univ. College of Medicine, 245 N. 15th St., MS #488, Philadelphia, PA 19102 (e-mail: robert.moreland{at}drexelmed.edu).







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2009 by the American Physiological Society.